Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics
LXRX Price/Volume Stats
| Current price | $1.63 | 52-week high | $3.79 |
| Prev. close | $1.62 | 52-week low | $0.92 |
| Day low | $1.62 | Volume | 3,715,000 |
| Day high | $1.73 | Avg. volume | 4,482,112 |
| 50-day MA | $2.35 | Dividend yield | N/A |
| 200-day MA | $1.71 | Market Cap | 401.37M |
LXRX Stock Price Chart Interactive Chart >
Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
Latest LXRX News From Around the Web
Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall StreetWall Street analysts foresee up to 316% upside in three fast-paced companies in the new year. |
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceTHE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th. Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, an |
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update AAK1 Disclosed as Drug Target for DMD Program On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced that AAK1 is the drug target for the company’s Duchenne muscular dystrophy (DMD) program, that SAT-3247 has been nominated as the lead drug candidate, and that IND-enabling studies and GMP |
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRE |
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx ConferenceTHE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Cr |
LXRX Price Returns
| 1-mo | -34.54% |
| 3-mo | 25.38% |
| 6-mo | 44.25% |
| 1-year | -33.47% |
| 3-year | -66.60% |
| 5-year | -70.79% |
| YTD | 6.54% |
| 2023 | -19.90% |
| 2022 | -51.52% |
| 2021 | 15.20% |
| 2020 | -17.59% |
| 2019 | -37.50% |
Continue Researching LXRX
Want to do more research on Lexicon Pharmaceuticals Inc's stock and its price? Try the links below:Lexicon Pharmaceuticals Inc (LXRX) Stock Price | Nasdaq
Lexicon Pharmaceuticals Inc (LXRX) Stock Quote, History and News - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...